118 results
6-K
TAK
Takeda Pharmaceutical Co
9 May 24
Current report (foreign)
6:01am
) Basic Management Policy
(2) Business Environment, Mid- to Long-term Business Strategy and Issues to Be Addressed
3. Basic Approach to the Section … and society while also sustaining positive impact for our people, communities, and the planet.
(2) Business Environment, Mid- to Long-Term Business Strategy
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
communication strategy and community engagement.
SAGE reviewed data across 19 Phase 1, 2 and 3 trials with more than 28,000 children and adults, including … strategy for enhancing our R&D pipeline. Our strategy to expand and diversify our external partnerships allows us to take part in research of a wide
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:18am
, Mr. Furuta served as corporate strategy officer and chief of staff at Takeda, and has held multiple leadership roles with the company around
6-K
TAK
Takeda Pharmaceutical Co
16 Jan 24
Current report (foreign)
6:01am
The Company Split is part of Takeda’s strategy to streamline the ownership structure of its subsidiaries and create a more adaptable and robust product
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
14 Dec 23
Current report (foreign)
6:01am
contributes to the corporate value of the Company Group by considering the Company’s mid-to-long term business strategy, and comparing the benefits … of the review, the Company divests shares from shareholdings that are deemed to be of little significance after taking the financial strategy and market
6-K
u6r1j5o rqd7kw239yo
30 Oct 23
Current report (foreign)
6:02am
6-K
ba16iz zcnjbv6
1 Aug 23
Current report (foreign)
6:10am
6-K
EX-99.1
82e2weknq96ylui38
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
l2ql2btwoliutkm hj
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
t3k07uj2cwxnulxvttcj
23 Jun 23
Current report (foreign)
6:13am
6-K
lo6ml2s
9 Jun 23
Current report (foreign)
6:03am
6-K
yjqnu r5yp0sy
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
s8qemsi7j2vs2qawe
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
n7jpumlq2yfkmo xh
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
jifbdufjhn ohr
30 May 23
Current report (foreign)
6:11am
6-K
19ouf
11 May 23
Current report (foreign)
6:07am
6-K
2n43yl7n30ozd z5
30 Mar 23
Current report (foreign)
6:19am
6-K
EX-99.1
tl2hwpugqx0ef0g
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am